MannKind Reports the US FDA’s sBLA Acceptance of Afrezza (Inhaled Insulin) for Children and Adolescents with Diabetes

Shots: The US FDA has accepted sBLA of Afrezza (insulin human) Inhalation Powder for the treatment of children & adolescents with type 1 or type 2 diabetes (PDUFA: May 29, 2026) sBLA was supported by P-III (INHALE-1), assessing Afrezza vs multiple daily injections (MDI), both in addition to basal insulin among type1/2 diabetic pts (4-17yrs.)…

ByRidhi RastogiOctober 14, 2025

THOUGHTSPOT

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Shots: With an incurable nature and hefty medication costs, diabetes mellitus remains a global health concern and the seventh leading cause of death across the world. The 2021 data reflects 537M affected people, with the predominant population living in low- and middle-income countries Type 2 diabetes mellitus (T2DM), unlike Type 1 diabetes mellitus (T1DM) is…

BySaurabh ChaubeyApril 13, 2023

MannKind Reports the US FDA’s sBLA Acceptance of Afrezza (Inhaled Insulin) for Children and Adolescents with Diabetes

Keeping Up with Recent Diabetes Therapies (Diabetes Mellitus)

Contact US

OUR INFORMATION

FOLLOW US